Literature DB >> 8821654

Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection.

R Levi1, R Arnon.   

Abstract

Synthetic vaccines utilize specific antigenic epitopes in order to elicit a protective immune response. In this work we examined the immunogenicity of chimeric proteins expressing influenza epitopes and their ability, as single products or in various combinations, to protect mice from viral challenge. Oligonucleotides coding for three epitopes (HA91-108, NP55-69 and NP147-158) stimulating B cells, T helper cells and cytotoxic T lymphocytes (CTLs), respectively, were individually inserted into the flagellin gene of a Salmonella vaccine strain. Immunization of mice with the resultant hybrid flagella resulted in a specific humoral or cellular response. The protective efficacy of the chimeric flagella was evaluated by intranasal immunization of mice, without any adjuvant, and subsequent challenge with infectious virus. The construct containing the B-cell epitope by itself led to partial protection. However, the addition of the two T-cell epitopes augmented the protection in a significant manner. The protective immunity conferred by this combined vaccine, comprising the three epitopes, persisted for at least 7 months after the last boost, and was effective against several influenza A strains. Furthermore, this vaccine fully protected mice from a lethal challenge, and enhanced their recovery process. Our results indicate that stimulation of the different arms of the immune system is required for effective anti-influenza response, and demonstrate the applicability of such synthetic recombinant approach for preparing a broad spectrum influenza vaccine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821654     DOI: 10.1016/0264-410x(95)00088-i

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.

Authors:  T Ben-Yedidia; R Tarrab-Hazdai; D Schechtman; R Arnon
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.

Authors:  John T Bates; Aaron H Graff; James P Phipps; Jason M Grayson; Steven B Mizel
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

3.  A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.

Authors:  Kristen N Delaney; James P Phipps; John B Johnson; Steven B Mizel
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

Review 4.  Effects of flagellin on innate and adaptive immunity.

Authors:  Anna N Honko; Steven B Mizel
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

Authors:  Jacob Atsmon; Efrat Kate-Ilovitz; Dimitry Shaikevich; Yossi Singer; Inna Volokhov; Kirsten Y Haim; Tamar Ben-Yedidia
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

Review 6.  Flagellin as an adjuvant: cellular mechanisms and potential.

Authors:  Steven B Mizel; John T Bates
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

7.  Mucosal adjuvant activity of flagellin in aged mice.

Authors:  John T Bates; Anna N Honko; Aaron H Graff; Nancy D Kock; Steven B Mizel
Journal:  Mech Ageing Dev       Date:  2008-02-17       Impact factor: 5.432

Review 8.  Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines.

Authors:  Shishir Kumar Gupta; Preety Bajwa; Rajib Deb; Madhan Mohan Chellappa; Sohini Dey
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

9.  Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.

Authors:  Steven B Mizel; Aaron H Graff; Nammalwar Sriranganathan; Sean Ervin; Cynthia J Lees; Mark O Lively; Roy R Hantgan; Michael J Thomas; James Wood; Brian Bell
Journal:  Clin Vaccine Immunol       Date:  2008-11-05

10.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.